SCHEMBL2622322

SCHEMBL2622322

Cc1cc(O)c2c(c1)-c1cc(O)c(Cl)c(O)c1C2=O

nearest known ligand 0.91

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACLY P53396 10/20 0.91
▸ ELANE P08246 4/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ MAPT P10636 3/20 0.56
▸ PIM1 P11309 3/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ CYP3A4 P08684 2/20 0.56
▸ TSHR P16473 2/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ TDP1 Q9NUW8 2/20 0.56
▸ ALOX15 P16050 2/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ PTP4A3 O75365 1/20 0.56
▸ GMNN O75496 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ ESR1 P03372 1/20 0.56
▸ TP53 P04637 1/20 0.56
▸ CYP1A1 P04798 1/20 0.56
▸ CYP1A2 P05177 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38662862 0.95 ACLY (1.00) ACLYELANEALDH1A1MAPTPIM1
SCHEMBL4743858 0.95 ACLY (1.00) ACLYELANEALDH1A1MAPTPIM1
SCHEMBL10905885 0.82 ACLY (0.72) ACLYELANEALDH1A1MAPTPIM1
SCHEMBL29359760 0.82 ACLY (0.72) ACLYELANEALDH1A1MAPTPIM1
SCHEMBL27879740 0.80 ACLY (1.00) ACLYELANEALDH1A1MAPTPIM1
SCHEMBL30940070 0.79 ACLY (0.73) ACLYELANEALDH1A1MAPTPIM1
SCHEMBL23199021 0.79 ACLY (0.72) ACLYELANEALDH1A1MAPTPIM1
SCHEMBL12304029 0.78 ELANE (0.85) ACLYELANEALDH1A1MAPTPIM1
SCHEMBL2622317 0.76 ACLY (0.69) ACLYELANEALDH1A1MAPTPIM1
SCHEMBL29859596 0.76 ACLY (0.69) ACLYELANEALDH1A1MAPTPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757407-B2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2017-09-12 — — US disclosed
US-9757407-B2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2017-09-12 — — US disclosed
US-20160346309-A1 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS UNIV PRINCETON (US) 2016-12-01 — — US disclosed
US-20160346309-A1 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS UNIV PRINCETON (US) 2016-12-01 — — US disclosed
US-9029413-B2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2015-05-12 — — US disclosed
US-9029413-B2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2015-05-12 — — US disclosed
EP-2581081-A2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2013-04-17 — — EP disclosed
EP-2572712-A2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2013-03-27 — — EP disclosed
US-20130065850-A1 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2013-03-14 — — US disclosed
US-8158677-B2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2012-04-17 — — US disclosed
US-8158677-B2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2012-04-17 — — US disclosed
US-20090239830-A1 Treatment of viral infections by modulation of host cell metabolic pathways KADMON CORPORATION, LLC 2009-09-24 — — US disclosed
US-20090239830-A1 Treatment of viral infections by modulation of host cell metabolic pathways KADMON CORPORATION, LLC 2009-09-24 — — US disclosed
WO-2009023059-A2 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2009-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239830-A1 Treatment of viral infections by modulation of host cell metabolic pathways GOT2, MAVS, ME3 ACLY 201/4885ELANE 3679/4885ALDH1A1 1469/4885
US-20160346309-A1 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS GOT2, MAVS, ME3 ACLY 201/4885ELANE 3679/4885ALDH1A1 1469/4885
US-20130065850-A1 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS GOT2, MAVS, ME3 ACLY 201/4885ELANE 3679/4885ALDH1A1 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback